Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

BACKGROUND: As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to improve lung function in moderate and severe COPD but i...

Descripción completa

Detalles Bibliográficos
Autores principales: Rennard, Stephen I, Calverley, Peter MA, Goehring, Udo M, Bredenbröker, Dirk, Martinez, Fernando J
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040135/
https://www.ncbi.nlm.nih.gov/pubmed/21272339
http://dx.doi.org/10.1186/1465-9921-12-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040135/
https://www.ncbi.nlm.nih.gov/pubmed/21272339
http://dx.doi.org/10.1186/1465-9921-12-18

Ejemplares similares